Literature DB >> 29498740

Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies.

Giulia Freer1, Mauro Pistello2.   

Abstract

Varicella-zoster virus (VZV) is the etiologic agent of varicella (chicken pox), a childhood exanthematic disease that develops as a result of primary infection, and zoster (shingles), caused by reactivation of the virus persisting in a latent form in the dorsal sensory ganglia. Although varicella is generally a mild self-limiting illness, in immunocompromised subjects and adults it can have a serious clinical course that can lead to permanent damage of the central nervous system. In these and in most zoster cases, treatment with anti-herpetic drugs and/or immunotherapy is necessary. Because it is highly contagious, varicella is one of the most common exanthematic diseases. It is preventable by vaccination with an attenuated vaccine administered around the first year of age, and with a boost vaccination in school age. This article briefly describes the natural history and pathophysiology of VZV infection and its current epidemiology and provides an overview of current and future vaccine options to protect against varicella and/or zoster.

Entities:  

Keywords:  Chickenpox; OKA vaccine strain; VZV vaccine; Varicella-zoster virus; Zoster

Mesh:

Substances:

Year:  2018        PMID: 29498740

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  23 in total

Review 1.  [Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].

Authors:  Alexander Winkelmann; Micha Löbermann; Uwe K Zettl
Journal:  Nervenarzt       Date:  2019-12       Impact factor: 1.214

2.  Chickenpox in an elderly man.

Authors:  Marcus G Tan; Jennifer Beecker
Journal:  Can Fam Physician       Date:  2020-08       Impact factor: 3.275

3.  Antiviral bioactivity of renewable polysaccharides against Varicella Zoster.

Authors:  Eiman Abu-Galiyun; Mahmoud Huleihel; Oshrat Levy-Ontman
Journal:  Cell Cycle       Date:  2019-11-14       Impact factor: 4.534

4.  Vulnerability of community-based isolation: a case of concurrent COVID-19 and primary varicella infection.

Authors:  Pei Hua Lee; Poh Lian Lim
Journal:  Singapore Med J       Date:  2020-07-30       Impact factor: 3.331

Review 5.  Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity.

Authors:  Bart N Ford; Jonathan Savitz
Journal:  Immun Ageing       Date:  2022-07-14       Impact factor: 9.701

6.  Radiotherapy Increases the Incidence of Herpes Zoster in Oral Cavity Cancer Patients - a National Population-based Cohort Study.

Authors:  Yung-Shuo Kao; Yen Hsu; Chung Y Hsu
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

7.  Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.

Authors:  Erin M Paradis; Oleg Tikhonov; Xin Cao; Susanna M Kharit; Aleksandr Fokin; Heather L Platt; Natalie Banniettis
Journal:  Hum Vaccin Immunother       Date:  2021-09-02       Impact factor: 4.526

8.  Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge.

Authors:  Kaitlin Winter; Li Xing; Audrey Kassardjian; Brian J Ward
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

9.  Herpes zoster after inactivated COVID-19 vaccine: A cutaneous adverse effect of the vaccine.

Authors:  Pooja Arora; Kabir Sardana; Sinu Rose Mathachan; Purnima Malhotra
Journal:  J Cosmet Dermatol       Date:  2021-06-15       Impact factor: 2.189

Review 10.  Emerging Themes for the Role of Antibodies in Tuberculosis.

Authors:  Andy C Tran; Mi-Young Kim; Rajko Reljic
Journal:  Immune Netw       Date:  2019-07-29       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.